Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2752 • 2014 ACR/ARHP Annual Meeting
Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Emire Seyahi¹, Erkan Caglar², Serdal Ugurlu¹, Fatih Kantarci³, Vedat Hamuryudan¹, Abdullah Sonsuz⁴, Melike Melikoglu⁵, Sebahattin Yurdakul¹ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, ³Department of Radiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, ⁴Department of Gastroenterology, Cerrahpasa Medical Faculty of Istanbul Universit, Cerrahpasa Medical Faculty of Istanbul University, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose Behçet’s syndrome (BS) is a well recognized cause of Budd–Chiari syndrome (BCS), however, information about its clinical characteristics and outcome is limited. We had…
Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Paz Rodríguez-Cundín², Emma Beltrán³, Juan Sánchez Bursón Sr.⁴, Marina Mesquida⁵, Alfredo Adan⁵, M. Victoria Hernández⁶, Marisa Hernandez Grafella⁷, Elia Valls Pascual⁸, Lucía Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose Luis García Serrano¹³, Norberto Ortego-Centeno¹⁴, Jose M Herreras¹⁵, Alejandro Fonollosa¹⁶, Angel M. Garcia-Aparicio¹⁷, Olga Maiz Alonso¹⁸, Ana Blanco¹⁹, Ignacio Torre Salaberri²⁰, Cruz Fernández- Espartero²¹, Vega Jovani²², Diana Peiteado²³, Esperanza Pato²⁴, Juan Cruz²⁵, Carlos Férnandez Cid²⁶, Elena Aurrecoechea²⁷, Miriam García-Arias²⁸, Miguel Angel Caracuel-Ruiz²⁹, Carlos Alberto Montilla Morales³⁰, Antonio Atanes-Sandoval³¹, Félix Francisco³², Santos Insua³³, Senen González-Suárez³⁴, Maria Amalia Sanchez Andrade³⁵, Fernando Gamero³⁶, Luis Francisco Linares Ferrando³⁷, Fredeswinda Romero³⁸, A. Javier García-González³⁹, Raquel Almodóvar González⁴⁰, Enrique Minguez⁴¹, Carmen Carrasco Cubero⁴², Alejandro Olive⁴³, Julio Vázquez⁴⁴, Oscar Ruiz Moreno⁴⁵, Fernando Jiménez-Zorzo⁴⁵, Javier Manero⁴⁵, Santiago MuÑoz Fernandez⁴⁶, Javier Rueda-Gotor¹, Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Rheumatology. Hospital de Valme., Sevilla, Spain, ⁵Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁷Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, ⁸Rheumatology. Hospital Peset, Valencia, Spain, ⁹Ophthalmology. Hospital Peset, Valencia, Spain, ¹⁰H. Vall d'Hebron, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology. Hospital San Cecilio, Granada, Spain, ¹⁴Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, ¹⁶Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ¹⁷Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ¹⁸Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁹Ophthalmology. Hospital Donosti, San Sebastián, Spain, ²⁰Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ²¹Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, ²²Rheumatology. Hospital General de Alicante, Alicante, Spain, ²³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁴Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, ²⁵Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, ²⁶Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, ²⁷Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ²⁸Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁹Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, ³⁰Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ³¹Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ³²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ³³Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, ³⁴Rheumatology. Hospital Cabueñes, Gijón, Spain, ³⁵Hosp. Lucus Augusti, Lugo, Spain, ³⁶Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, ³⁷Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ³⁸Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³⁹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ⁴⁰Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ⁴¹Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, ⁴²Rheumatology, Hospital de Merida, Mérida, Spain, ⁴³Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ⁴⁴Rheumatology. Hospital de Ferrol, A Coruña, Spain, ⁴⁵Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ⁴⁶Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
Abstract Number: 2753 • 2014 ACR/ARHP Annual Meeting
Reduced Heart Rate Variability in Patients with Behcet’s Disease
Joung-Wook Lee¹, Seung-Geun Lee², Eun-Kyoung Park² and Geun-Tae Kim³, ¹Divsion of Rheumatology, Department of Internal Medicine, Busan St. Marys center, Busan, South Korea, ²Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
Background/Purpose The autonomic nervous system, including the sympathetic and parasympathetic nervous systems, has an important role in the triggering of ventricular arrhythmias and sudden cardiac…
Abstract Number: 2854 • 2014 ACR/ARHP Annual Meeting
Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet’s Syndrome
Gulen Hatemi¹, Melike Melikoglu¹, Recep Tunc², Cengiz Korkmaz³, Banu Turgut Ozturk⁴, Cem Mat⁵, Peter A. Merkel⁶, Kenneth Calamia⁷, Lilia Pineda⁸, Ziqi Liu⁸, Randall M. Stevens⁸, Hasan Yazici¹ and Yusuf Yazici⁹, ¹Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ³EskiÅŸehir Osmangazi University, EskiÅŸehir, Turkey, ⁴Selçuk University, Konya, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, ⁶Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Administration, Mayo Clinic Health System in Waycross, Waycross, GA, ⁸Celgene Corporation, Warren, NJ, ⁹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The oral ulcers in Behçet’s syndrome (BS) can be painful, causing difficulty in eating and speaking, and can impair the quality of life. Apremilast…
Abstract Number: 2732 • 2014 ACR/ARHP Annual Meeting
Massive Ex Vivo Expansion of Functionally Stable Behcet’s Patient-Derived Regulatory T Cell Clones
Johannes Nowatzky¹, Olivier Manches¹, Yusuf Yazici² and Juan Lafaille¹, ¹New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Adoptive transfer of regulatory T cells (Treg) is a promising strategy for the treatment of human autoimmune diseases. Most currently tested approaches focus on…
Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Peter C. Grayson¹, Yusuf Yazici², Elaine Novakovich³, Elizabeth Joyal⁴, Raphaela T. Goldbach-Mansky⁴ and Cailin H. Sibley^3,5, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, ⁵Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…
Abstract Number: 2208 • 2014 ACR/ARHP Annual Meeting
Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet’s Disease and Spondyloarthritis – Impact on Anti-Muellerian Hormone Levels
Joerg C. Henes¹, Julia Froeschlin², Andre Taran³, Theodoros Xenitidis⁴ and Melanie Henes⁵, ¹Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ²University Tuebingen, Tuebingen, Germany, ³University Hospital for Women Tuebingen, Tuebingen, Germany, ⁴Internal Medincine II, devision for Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁵University Hospital for Women, Tuebingen, Germany
Background/Purpose: Recent publications showed a negative influence of systemic lupus erythematosus and antiphospholipid antibody syndrome on female ovarian reserve (OR). Other authors did not find…
Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Hélène Vallet¹, Sophie Rivière², Alban Deroux³, Guillaume Moulis⁴, Olga Addimanda⁵, Carlo Salvarani⁶, Marc Lambert⁷, Philip Bielfeld⁸, Pascal Sève⁹, Jean Sibilia¹⁰, Jean Baptiste Fraison¹¹, Yoland Schoindre¹², Isabelle Marie¹³, Laurent Perard¹⁴, Thomas Papo¹⁵, Damien Sène¹⁶, Gaelle Leroux¹⁷, Valerie Royant¹⁸, Antoinette Perlat¹⁹, Xavier Mariette²⁰, Olivier Lidove²¹, Olivier Fain²², Claire De Moreuil²³, Gilles Blaison²⁴, Phuc LE Hoang²⁵, Eric Hachulla²⁶, Bertrand Wechsler²⁷, Barham Bodaghi²⁸, Patrice Cacoub²⁹ and David Saadoun³⁰, ¹Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal Medicine, Lapeyronie, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Internal Medicine department, Toulouse, Toulouse, France, ⁵S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, ⁶Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷CHRU Lille, Lille, France, ⁸CHU de Dijon, Dijon, France, ⁹Internal medicine, CHU Lyon, Lyon, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Hôpital Jean Verdier, Bondy, France, ¹²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, ¹³CHU de Rouen, Rouen, France, ¹⁴Hospices civils de Lyon, Lyon, France, ¹⁵Hôpital Bichat, Paris, France, ¹⁶Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁷Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ¹⁸Chartres, Chartres, France, ¹⁹Internal medicine, CHU de Rennes, Rennes, France, ²⁰rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ²¹Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, ²²Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ²³CHU, Brest, France, ²⁴Internal medicine, CHR, Colmar, France, ²⁵Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, ²⁶Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ²⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²⁸Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, ²⁹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ³⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…
Abstract Number: 1339 • 2014 ACR/ARHP Annual Meeting
Is Psychological Status Related to Symptom Experience in Behçet’s Syndrome?
Robert Moots¹ and Sophie Campbell², ¹Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Behcets Centre, Aintree University Hospital, Liverpool, United Kingdom
Background/Purpose Little is known about the impact of Behçet’s Syndrome (BS) within the UK. The recent establishment of National Centres of Excellence now allows a…
Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Salvatore D'Angelo¹, Pietro Leccese¹, Angela Padula¹, Angelo Nigro¹, Michele Gilio², Antonio Carriero¹, Carlo Palazzi¹ and Ignazio Olivieri¹, ¹Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²San Carlo Hospital, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…
Abstract Number: 1212 • 2014 ACR/ARHP Annual Meeting
Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator
Alex Wessel¹, Spiros Vonortas², Jevgenia Zilberman-Rudenko³, Richard Siegel⁴ and Eric Hanson⁵, ¹5814 Beech Ave, NIH, Bethseda, MD, ²NIH, NIAMS, Bethesda, MD, ³Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NIAMS, NIH, Bethesda, MD, ⁵National Institute of Health, Bethesda, MD
Background/Purpose: Behçet's disease (BD) is a chronic multi-system inflammatory disorder associated clinically with oral and genital ulceration, uveitis, erythema nodosum, and other inflammatory disease. The…
Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Yasin Keskin¹, Emire Seyahi², Cagri Poyraz³, Serdal Ugurlu¹, Yilmaz Ozyazgan⁴ and Hasan Yazici⁵, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Psychiatry, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Istanbul, Turkey, ⁴Department of Ophthalmology, Cerrahpasa Medical Faculty University of Istanbul, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…
Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Hirotoshi Kikuchi¹, Kurumi Asako¹, Maki Takayama¹, Yoshitaka Kimura¹, Akiko Okamoto¹, Toshihiro Nanki^1,2, Hajime Kono¹ and Shunsei Hirohata³, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Department of Clinical Research Medicine, Teikyo University, Tokyo, Japan, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…
Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Shunsei Hirohata¹, Hirotoshi Kikuchi², Tetsuji Sawada³, Hiroko Nagafuchi⁴, Msataka Kuwana⁵, Mitsuhiro Takeno⁶ and Yoshiaki Ishigatsubo⁷, ¹Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, ⁴Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁵Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, ⁷Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…
Abstract Number: 1905 • 2013 ACR/ARHP Annual Meeting
Protein Profiles Of Peripheral Blood Mononuclear Cells As a Biomarker For Behcet’s Disease
Manae Kurokawa¹, Takuya Yoshioka², Toshiyuki Sato¹, Kouhei Nagai¹, Nobuko Iizuka¹, Mitsumi Arito¹, Yukiko Takakuwa², Hiromasa Nakano², Seido Ooka², Naoya Suematsu¹, Kazuki Okamoto¹, HIroshi Nakamura³, Noboru Suzuki⁴, Shoichi Ozaki⁵ and Tomohiro Kato¹, ¹Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Department of Rheumatology, Nippon Medical School, Bunkyo-ku, Japan, ⁴Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: To investigate the pathophysiology of Behcet’s disease (BD) and find biomarker candidates for the disease, we analyzed protein profiles of peripheral blood mononuclear cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].